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Background: An association between cigarette smoking and increased risk of clear cell renal cell carcinoma (ccRCC) has
been established; however, there are limited data regarding the molecular mechanisms that underlie this association. We
used a multi-stage design to identify and validate genes that are associated with smoking-related ccRCC.
Methods: We first conducted a microarray study to compare gene expression patterns in patient-matched ccRCC
and normal kidney tissues between patients with (n = 23) and without (n = 42) a history of smoking. Analyses were first
stratified on obesity status (the other primary risk factor for ccRCC) and then combined and analyzed together.
To identify genes where the fold change in smokers relative to non-smokers was different in tumor tissues in
comparison to patient-matched normal kidney tissues, we identified Affymetrix probesets that had a significant tissue
type-by-smoking status interaction pvalue. We then performed RT-PCR validation on the top eight candidate genes in
an independent sample of 28 smokers and 54 non-smokers.
Results: We identified 15 probesets that mapped to eight genes that had candidate associations with smoking-related
ccRCC: ANKS1B, ACOT6, PPWD1, EYS, LIMCH1, CHRNA6, MT1G, and ZNF600. Using RT-PCR, we validated that expression
of ANKS1B is preferentially down-regulated in smoking-related ccRCC.
Conclusion: We provide the first evidence that ANKS1B expression is down regulated in ccRCC tumors relative to
patient-matched normal kidney tissue in smokers. Thus, ANKS1B should be explored further as a novel avenue for early
detection as well as prevention of ccRCC in smokers.Background
Currently, cigarette smoking is an established risk factor
for the development of clear cell renal cell carcinoma
(ccRCC) [1]. Indeed, authors of a meta-analysis involving
26 epidemiologic studies spanning 37 years concluded that
the risk of ccRCC among ever smokers is approximately
40% higher compared to lifetime never smokers [2]. From
a population-based perspective, previous investigators have
suggested that cigarette smoking alone accounts for
approximately 20-25% of the ccRCCs diagnosed in the
U.S. [3,4]. While smoking is an established risk factor
for ccRCC, what remain unclear are the specific somatic
molecular alterations that underlie this well-reported
association. Identification of specific alterations at the
cellular level that link smoking to ccRCC development
has the potential to further solidify a causal association,* Correspondence: parker.alexander@mayo.edu
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distribution, and reproduction in any mediumadvance our understanding of the etiology of this disease
and possibly extend even further into more focused
measures of early detection and prevention.
To address the need to better understand the molecular
underpinnings of smoking-related ccRCC, we sought to
identify candidate genes that are differentially expressed
in ccRCC tumors that develop in smokers compared to
non-smokers. Thus, we employed the Affymetrix U133
Plus 2.0 platform to compare somatic gene expression
profiles between patient-matched ccRCC and normal
kidney tissues from patients with and without a history of
smoking, controlling for obesity status (the other primary
risk factor for ccRCC [4,5]). Although other risk factors
have been reported in the literature, smoking and obesity
are the only epidemiological risk factors that have been
consistently validated as increasing risk of ccRCC. Fol-
lowing our microarray-based discovery efforts, we then
validated our top candidate genes by employing RT-PCR
on an independent set of ccRCC and patient-matched
normal kidney tissue samples from smokers and non-entral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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ANKS1B is a smoking-related alteration in ccRCC.
Methods
Ethics statement
This study was approved by the Mayo Clinic Institutional
Review Board. All participants provided written consent
to participate in this study.
Overview
For this investigation, we employed a multi-stage design
that allowed us to take into account potential confounding
effects of obesity, the other consistently-reported risk
factor of ccRCC [5], and seek validation of our top candi-
date genes. Briefly, in stage 1 we only considered non-
obese subjects and used the Affymetrix platform on
patient-matched ccRCC and normal kidney tissues from
smokers and non-smokers to identify candidate smoking-
related gene expression changes in ccRCC. In stage 2, we
again used the Affymetrix platform on patient-matched
ccRCC and normal kidney tissues from smokers and
non-smokers; however, this time we included only obese
subjects. That is, we aimed to identify smoking-related
genes that were not dependent on obesity status. With
the list of candidate genes narrowed down, in stage 3
we performed RT-PCR validation on the top candidates
in an independent set of patient-matched ccRCC and
normal kidney tissues. We provide more detail on the
design and selection of the subjects for each stage in
the sections below.
Patient selection
Stage 1: Affymetrix microarrays on non-obese ccRCC subjects
The objective of stage 1 was to perform a genome-wide
scan and identify candidate genes that are associated with
smoking-related ccRCC. To do so, we compared gene
expression between patients with and without a history
of smoking across patient-matched tumor and normal
kidney samples. Upon approval from our Institutional
Review Board, we identified patients treated with radical
nephrectomy or nephron-sparing surgery for unilateral,
sporadic ccRCC between 2000 and 2006 from our Neph-
rectomy Registry. We then excluded all patients with a
body mass index (BMI) > 30 kg/m2 as well as patients with
late stage tumors (pT4) and patients with high-grade
tumors (grade 4). The decision to remove patients with
a BMI > 30 in stage 1 was based on the fact that obesity
represents the only other widely reproducible risk factor
for ccRCC development and thus we wanted to match by
obesity status. The removal of late-stage and high-grade
subjects was based on our desire in stage 1 to identify
changes that occur early in ccRCC carcinogenesis. Based
on these criteria, we identified 46 non-obese subjects that
had both fresh-frozen normal kidney and tumor tissueavailable for study; 16 of which had a history of smoking
and 30 had no history of smoking. We obtained smoking
data from risk factor questionnaires completed at time of
surgery and from medical chart review where necessary.
Using these data, we defined non-smokers as anyone who
reported never smoking cigarettes on the questionnaire or
to their physician during a standard patient history taken
prior to surgery. For smokers, we required that the subject
report greater than 20 pack-years of smoking on either the
questionnaire or during the patient history.
Stage 2: Affymetrix microarrays on obese ccRCC subjects
As noted above, because obesity is the other widely ac-
ceptable risk factor and we wanted to identify molecular
markers that were not dependent on obesity status, we
performed a two-stage design stratifying by obesity status.
Thus, we repeated our design and analysis from stage 1
but this time we only used obese subjects. Our rationale
for this second stage of discovery is that by moving into
an obese population we would have the opportunity to
further screen the candidates from stage 1 by looking for
genes that still have a smoking-related expression signal
even among subjects with another primary risk factor
for ccRCC. The subjects in stage 2 were similar to stage
1 (i.e. unilateral, sporadic, pT stage 1-3, grade 1-3) with
the exception that they all had a BMI > 30 kg/m2 at
time of surgery. As such, stage 2 consisted of 19 obese
ccRCC subjects that had both fresh-frozen normal kidney
and tumor tissue available for study; 7 of which had a
history of smoking and 12 had no history of smoking. We
used the same criteria to define smokers and non-smokers
as described above for stage 1.
Stage 3: RT-PCR validation on non-obese ccRCC subjects
With our discovery-based steps complete, the objective
of stage 3 was to seek independent validation of the can-
didate genes we identified in stages 1-2. The patients in
stage 3 consisted of 82 non-obese patients that had both
fresh-frozen normal kidney and tumor tissue available
for study; 28 of which had a history of smoking and 54
had no history of smoking. For this important validation
step we moved back into the setting of only evaluating
non-obese patients to allow for the most robust chance
of validation. For this validation stage, we used the same
criteria to define smokers and non-smokers as described
above for stage 1.
Tissue preparation and laboratory assays
Tissue samples
An experienced urologic pathologist identified fresh-frozen
blocks with representative tumor and normal kidney tissue
for each patient involved in stages 1-3. For those patients
with a ccRCC tumor that showed mixed grade, the study
pathologist selected the block with the highest grade
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selected, a histotechnologist macrodissected two five-mi-
cron sections from each of the fresh-frozen tumor and
corresponding normal kidney tissue blocks. The Mayo
Biospecimen Accessioning and Processing Core performed
RNA extractions using kits and protocols from the Qiagen
miRNEasy kit and Qiagen Qiacube instrument. The RNA
was DNAse treated on the column prior to elution. We
assessed RNA quantity and quality using Nanodrop Spec-
trophotometer and Agilent.
Affymetrix microarrays
Microarray analysis was conducted according to manufac-
turer’s instructions for the Affymetrix One Cycle Target
Labeling and Control Reagents kit (Santa Clara, CA).
Briefly, cDNA was generated from five micrograms of
total RNA using SuperScript II reverse transcriptase
(Invitrogen, Carlsbad, CA) and T7 Oligo(dT) primer.
Subsequently, the products were column-purified (Affyme-
trix) and then in vitro transcribed to generate biotin-labeled
cRNA. The IVT products were then column-purified,
fragmented, and hybridized onto Affymetrix U133
Plus 2.0 GeneChips® at 45°C for 16 h. Subsequent to
hybridization, the arrays were washed and stained with
streptavidin-phycoerythrin, then scanned in an Affymetrix
GeneChip® Scanner 3000 (Santa Clara, CA). All control
parameters were confirmed to be within normal ranges
before normalization was initiated. The data discussed
in this publication have been deposited in NCBI’s Gene
Expression Omnibus and are accessible through GEO
Series accession number GSE46699 (http://www.ncbi.
nlm.nih.gov/geo/query/acc.cgi?acc=GSE46699).
Microarray data normalization and statistical methods
The data used herein are comprised of two batches of
samples that were processed at two different time periods
(see Supplementary Methods in [6]). Base-2 logarithm
transformed intensity data from the two batches of
samples were normalized within each batch using frozen
robust multi-array analysis (frozen RMA) [7]. Frozen
RMA was specifically designed to preprocess arrays in
batches and subsequently allow the data to be combined
for downstream analyses.
The samples used in stage 1 and stage 2 are shown in
Figure 1. Stage 1 and stage 2 data were analyzed separately
and then combined and analyzed as a whole. Linear mixed
models were fit to the normalized intensity data for
each probeset. Within the linear mixed model, tissue
type (tumor/normal), smoking status (smoker/non-smoker)
and a smoking status-by-tissue type interaction were
included as fixed effects while a random intercept was
fit on a per patient basis to account for the patient-matched
tumor and normal samples. The smoking status-by-tissue
type interaction was included to identify probesets wherethe fold change between smokers versus non-smokers
was different in tumor in comparison to normal tissue.
Probesets with a smoking status-by-tissue type inter-
action p-value <0.01 in stage 1 were identified as having
a potential association with smoking-specific alterations
in ccRCC and therefore were determined to be good
candidates for further evaluation in stage 2. We acknow-
ledge that this p-value threshold does not account for
multiple testing at the conservative Bonferroni level.
However, probesets that are consistently identified in
stage 1 at this nominal significance and subsequently in
stage 2 with a smoking status-by-tissue type interaction
pvalue <0.05 and then maintained a smoking status-by-
tissue type interaction p-value <0.01 in the analysis of
the combined data were deemed to be good candidates
for further validation in stage 3. To determine how the
fold change differed across tumor and normal specimens,
we also calculated the fold change of normalized expres-
sion for smokers versus non-smokers in normal tissue as
well as the fold change of smokers versus non-smokers
tumor tissue. All statistical tests were performed using a
Linux release of R version 2.14. All probeset-to-gene map-
ping was done using the hgu133plus2.db (version 2.9.0).
Gene expression by fluidigm quantitative PCR
Samples were reverse transcribed according to the man-
ufacturer’s instructions for the High Capacity Reverse
Transcription kit (Applied Biosystems, Foster City, CA).
Briefly, 50 ng of total RNA was reverse transcribed in a
20 μl reaction mixture containing 0.8 μl of 100 nM
dNTP, 2.0 μl RT buffer, 1.0 μl of reverse transcriptase
(50U/μl), 2 μl of RT primer. The reaction mixture was
mixed and incubated as follows; 25°C for 10 min, 37°C
for 2 h, and then 85°C for 5 min, followed by a 4°C hold.
Pre-amplification of cDNA was initiated by creating a pool
of 24 TaqMan mRNA Assays at a final concentration of
0.2X for each assay. The pre-PCR amplification reac-
tion was then performed in a 5 μl reaction mixture
containing 2.5 μl TaqMan PreAmp Master Mix (2X),
1.25 μl of 24-pooled TaqMan assay mix (0.2X) and 1.25 μl
of cDNA. The pre-amplification PCR was performed
according to the following cycling conditions: one cycle
95°C for 10 min, 14 cycles at 95°C for 15 sec and then
60°C for 4 min. After pre-amplification PCR, the product
was diluted 1:5 with dH2O and stored at -20°C until
needed for amplification.
Quantitative PCR of the mRNA targets was carried
out using the 48.48 dynamic array (Fluidigm, South San
Francisco, CA) following the manufacturer’s protocol.
Briefly, a 5 μl sample mixture was prepared for each
sample containing 2x TaqMan Universal Master Mix
(with UNG), 20X GE Sample Loading Reagent and each
of diluted pre-amplified cDNA. Five microliters of Assay
































Figure 1 Experimental design for stage 1 and stage 2. *Normal tissue did not pass RNA or microarray quality-control metrics for 4 normal
tissue samples.
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The dynamic array was primed with control line fluid in
the IFC controller and samples and assay mixes was
loaded into the appropriate inlets. The chip was then
returned to the IFC controller for loading and mixing,
and then placed in the BioMark Instrument for PCR at
50°C for 2 min and 95°C for 10 min, followed by 40
cycles at 95°C for 15 sec and 60°C for 1 min. The data
were analyzed with the Real-Time PCR Analysis Soft-
ware (Fluidigm, South San Francisco, CA).
RT-PCR data normalization and statistical methods
Normalization was carried out as discussed previously [8].
In brief, the negative CT (denoted hereafter as -CT) values
for the two control genes (POLR2A and ACTB) were aver-
aged on a per sample basis and the average was subtracted
from the -CT value for each sample. As was done for the
Affymetrix microarray data, linear mixed models were fitto the normalized –CT data for each gene. Within the lin-
ear mixed model, tissue type (tumor/normal), smoking sta-
tus (smoker/non-smoker) and a smoking status-by-tissue
type interaction were included as fixed effects while a ran-
dom intercept was fit on a per patient basis.
Results
Patient characteristics
We provide a comparison of demographic and clinical
characteristics between smokers and non-smokers for
the patients in each of the three stages of our study in
Table 1. Although in all three stages there was a trend
for smokers to more likely be male than the non-smokers,
this trend was only statistically significant in stage 3. In con-
trast, we observed no differences in age categories or in
tumor grade between smokers and non-smokers across the
three stages. In stage 1, smokers were more likely to have
later stage disease compared to non-smokers; however, the
Table 1 Demographic and clinicopathologic characteristics for subjects in each stage of the multi-stage design
Affymetrix microarray RT-PCR














Gender 0.2170 0.1698 0.0273
Male 14 (47%) 11 (69%) 4 (33%) 5 (71%) 30 (56%) 23 (82%)
Female 16 (53%) 5 (31%) 8 (67%) 2 (29%) 24 (44%) 5 (18%)
Age at surgery 0.2537 0.8584 0.4597
<50 3 (10%) 3 (19%) 2 (17%) 1 (14%) 9 (17%) 5 (18%)
50-79 24 (80%) 13 (81%) 9 (75%) 6 (86%) 41 (76%) 23 (82%)
≥80 2 (7%) 0 1 (8%) 0 4 (7%) 0
Unknown 1 (3%) 0 0 0 0 0
Nuclear grade 0.2032 0.5834 0.2000
1 3 (10%) 1 (6%) 4 (33%) 2 (29%) 5 (9%) 3 (11%)
2 18 (60%) 7 (44%) 8 (67%) 4 (57%) 17 (32%) 7 (25%)
3 9 (30%) 8 (50%) 0 1 (14%) 24 (44%) 11 (39%)
4 0 0 0 0 8 (15%) 7 (25%)
Pathologic tumor stage 0.0123 0.5926 0.4713
pT1 24 (80%) 7 (44%) 9 (75%) 6 (86%) 31 (57%) 11 (39%)
pT2 2 (7%) 2 (12%) 2 (17%) 1 (14%) 4 (7%) 4 (14%)
pT3 4 (13%) 7 (44%) 1 (8%) 0 18 (33%) 13 (46%)
pT4 0 0 0 0 1 (2%) 0
Presence of necrosis 0.2829 1.0000 0.4739
Yes 5 (17%) 5 (31%) 1 (8%) 1 (14%) 19 (35%) 13 (46%)
No 25 (83%) 11 (69%) 11 (92%) 6 (86%) 34 (63%) 15 (54%)
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smokers among patients in stages 2-3. Finally, across all
three stages, there was no significant difference in pres-
ence of necrosis in smokers compared to non-smokers.
Discovery of genes associated with smoking-related
ccRCC (stage 1 and stage 2 results)
We identified 305 probesets that had a smoking status-by-
tissue type interaction p-value <0.01 in stage 1 (non-obese
cohort). Of the 305 probesets we identified in stage 1,
15 also had a smoking status-by-tissue type interaction
p-value <0.05 in stage 2 (obese cohort) and maintained
a p-value <0.01 in the analysis of the combined data
(Table 2). Of these 15 probesets, only nine were mapped
to known genes. Due to the fact that the Affymetrix
platform contains multiple probesets that map to the
same gene, in addition to showing the 15 probesets that
met our pre-defined filtering criteria, Additional file 1
provides results for all additional probesets that map to
these 9 genes and demonstrates that the fold change
estimates are consistent across probesets that map to the
same gene. In normal kidney tissue ANKS1B, ACOT6,
EYS, CHRNA6, MT1G and UTY were up regulated in
smokers in comparison to non-smokers; however, these
genes tended to be down regulated in smokers versus
non-smokers in ccRCC tumor tissue. Conversely, in normal
kidney tissue PPWD1, LUMCH1 and ZNF600 were down
regulated in smokers compared to non-smokers; how-
ever, these genes were up regulated in smokers versus
non-smokers in ccRCC tumor tissue. We selected eight
of these nine candidate genes for follow-up validation
using RT-PCR in stage 3; we chose not to attempt to
validate UTY since it is located on chromosome Y and
likely reflects the fact that smokers were more likely to
be male than non-smokers.
Independent RT-PCR validation (stage 3 results)
Of the eight genes interrogated via RT-PCR in stage 3,
only ANKS1B validated as having an expression pattern
that was consistent with what was observed in stages 1
and 2 (Table 3). Specifically, in stage 1 (non-obese cohort)
ANKS1B had a tissue type-by-smoking status interaction
p-value of 0.0008; the fold change of expression between
smokers and non-smokers was 1.08 (p = 0.02) in normal
tissues and 0.92 (p = 0.01) in tumor tissues (Table 2).
These results were consistent in stage 2 (obese cohort)
with an interaction p-value of 0.018 and a fold change
of expression between smokers and non-smokers of
1.11 (p = 0.005) in normal tissue and 0.98 (p = 0.64) in
tumor tissue (Table 2). Furthermore, the additional 4
probesets that map to ANKS1B showed similar fold
change estimates as the proband probeset that met our
pre-defined filtering criteria (Additional file 1). Performing
RT-PCR on an independent cohort of 82 non-obesesubjects (stage 3), we validated these results with an
interaction p-value of 0.0051; the fold change of expression
between smokers and non-smokers was 1.35 (p = 0.06) in
normal tissues and 0.95 (p = 0.76) in tumor tissues.
Discussion
Based on the current literature, there is little question
regarding the role of cigarette smoking in the etiology of
ccRCC; however, what remains unclear is exactly how
smoking acts within the body (specifically within the
kidney itself ) to increase a person’s risk of developing
ccRCC. Related to this, tobacco smoke contains a vast
number of chemicals, with about 50 of those chemicals
being classified as human carcinogens [9]. Inhaled chemical
carcinogens from cigarette smoke, like any other chemical
that enters the human body, are subject to extensive
metabolism. The majority of this metabolism is directed
toward deactivation of the particular chemical and
eventual excretion. However, an important fraction of
the metabolic process results in the conversion of the
ingested compound to highly reactive metabolite(s) that
possess the ability to bind to intercellular components
(i.e. DNA) and induce changes in their structure; changes
that may or may not lead to the transformation of normal
cells to tumor cells. Given that the kidney is the main
filtration organ of the blood and is known to locally
produce enzymes involved in xenobiotic metabolism, it
is theorized to be at high exposure to any smoking-related
carcinogen. In fact, researchers have reported that the
urine of smokers has increased mutagenic activity compared
to non-smokers [10]. While this primary theory of how
smoking increases the risk of ccRCC does exist, little
progress has been made towards illuminating the actual
molecular target(s) that are altered by smoking carcinogens
in the development of ccRCC.
ANKS1B, Ankyrin repeat and sterile alpha motif domain-
containing protein 1B, is a tyrosine kinase signal transduc-
tion gene that is primarily expressed in the brain and testis.
Here, we demonstrate for the first time that expression
of the ANKS1B gene is associated with smoking-related
ccRCC development. ANKS1B is involved in apoptosis
and thus has the potential to play a key role in cancer
development [11]. From our observational data, we show
that ANKS1B is up regulated in smokers relative to
non-smokers in normal kidney tissue; however, it is
down regulated in smokers relative to non-smokers in
ccRCC tumor tissue. Thus, ANKS1B expression in smokers
is down regulated in the tumor tissue in comparison
to the patient-matched normal kidney tissue and this
down regulation is potentially a key event that supports
ccRCC development. Interestingly, Lin et al. [12] recently
evaluated the association of germline SNPs within
apoptotic pathway genes with lung cancer risk – in
which smoking is also a major risk factor – and identified





























240292_x_at ANKS1B 12 0.92 (0.013) 1.08 (0.02) 0.00082 0.98 (0.64) 1.11 (0.005) 0.018 0.94 (0.014) 1.09 (0.0013) 0.00005
241949_at ACOT6 14 0.88 (0.0098) 1.07 (0.15) 0.00085 0.89 (0.1) 1.04 (0.56) 0.034 0.88 (0.0019) 1.06 (0.13) 0.00006
236999_at PPWD1 5 1.13 (0.0062) 0.99 (0.74) 0.0015 1.2 (0.0034) 1.04 (0.5) 0.038 1.14 (0.00023) 1.0 (0.99) 0.00016
233996_x_at EYS 6 0.94 (0.022) 1.03 (0.27) 0.0022 1.0 (1) 1.06 (0.045) 0.046 0.96 (0.033) 1.04 (0.077) 0.00026
241459_at LIMCH1 4 1.27 (0.06) 0.89 (0.37) 0.0077 1.9 (0.0032) 1.09 (0.65) 0.02 1.43 (0.0011) 0.95 (0.62) 0.00047
207568_at CHRNA6 8 0.92 (0.24) 1.15 (0.064) 0.0075 0.95 (0.62) 1.23 (0.034) 0.037 0.93 (0.2) 1.17 (0.0069) 0.00058
210472_at MT1G 16 1.0 (0.97) 1.47 (0.00013) 0.0045 0.93 (0.62) 1.4 (0.032) 0.018 0.98 (0.82) 1.45 (0.0000099) 0.00061
242463_x_at ZNF600 19 1.48 (0.0064) 0.98 (0.87) 0.0077 1.78 (0.001) 1.31 (0.083) 0.045 1.56 (0.00013) 1.07 (0.53) 0.0012
210322_x_at UTY Y 0.98 (0.76) 1.13 (0.079) 0.0086 0.96 (0.72) 1.22 (0.075) 0.0093 0.98 (0.68) 1.16 (0.012) 0.00029
1557478_at NA NA 1.22 (0.03) 0.95 (0.55) 0.00052 1.88 (0.00002) 1.31 (0.022) 0.0011 1.38 (0.00012) 1.04 (0.62) 0.000002
1558410_s_at NA NA 1.42 (0.013) 0.93 (0.58) 0.0049 2.49 (0.0000087) 1.63 (0.0038) 0.017 1.66 (0.000044) 1.1 (0.44) 0.0006
210717_at NA NA 1.74 (0.00062) 0.89 (0.47) 0.0033 2.12 (0.00026) 1.41 (0.053) 0.027 1.83 (0.000011) 1.03 (0.8) 0.00086
232324_x_at NA NA 1.17 (0.004) 0.97 (0.52) 0.0081 1.27 (0.0018) 1.03 (0.61) 0.039 1.2 (0.000058) 0.99 (0.77) 0.0011
232369_at NA NA 1.36 (0.021) 0.89 (0.4) 0.0081 2.07 (0.00065) 1.3 (0.15) 0.031 1.53 (0.00016) 1.0 (0.99) 0.00078
244290_at NA NA 1.32 (0.0038) 0.99 (0.94) 0.0015 1.66 (0.000041) 1.26 (0.022) 0.033 1.4 (0.000035) 1.06 (0.42) 0.00019
The smoking status-by-tissue type interaction p-value is provided as well as the fold change of expression in smokers relative to non-smokers and corresponding p-values.
Chrom denotes chromosome.


















Table 3 RT-PCR results for stage 3









ANKS1B 12 0.95 (0.76) 1.35 (0.06) 0.0051
ACOT6 14 1.21 (0.53) 1.03 (0.92) 0.56
PPWD1 5 0.97 (0.66) 0.94 (0.44) 0.67
LIMCH1 4 1.04 (0.81) 1.05 (0.76) 0.93
CHRNA6 8 0.92 (0.71) 0.63 (0.038) 0.095
MT1G 16 1.15 (0.72) 1.27 (0.55) 0.80
ZNF600 19 1.05 (0.62) 1.00 (0.99) 0.52
The smoking status-by-tissue type interaction p-value is provided as are the
fold change of expression in smokers relative to non-smokers and
corresponding p-values.
Chrom denotes chromosome.
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had statistically significant associations. What remains
unclear is whether these SNPs are also found in lung
cancer tissues and whether they are functionally associated
with expression or activity of the ANKS1B protein. That
notwithstanding, these results from another smoking-
related cancer further suggest a possible role for ANKS1B
to be a smoking-related molecular alteration in cancer
and underscore the potential for these results to advance
the knowledge of ccRCC etiology and prevention. Indeed,
in addition to advancing our understanding of the path-
ways involved in smoking-related ccRCC, alterations in
ANKS1B could also potentially be used for early detec-
tion and prevention in smokers. That being said, we
acknowledge that our findings must first be validated at
the protein level. Moreover, there is a need to link alter-
ations in ANKS1B to smoking-related ccRCC in a more
robust epidemiologic study design. Particularly, using a
larger case–control study or a large prospective-cohort
study where it would be feasible to adjust for additional
reported risk factors, to study the dose–response rela-
tionship of smoking with ANKS1B and lastly, to study
the association of smoking with molecularly-defined
ccRCC subtypes.
We used a discovery-based approach to identify smok-
ing-specific molecular alterations associated with ccRCC
development that can be followed up in more focused
investigations. Having said that, the key limitations of our
approach include our focus on expression changes at the
RNA level (compared to protein expression or alterations
at DNA level) and our overall limited generalizability
(tertiary referral center, >95% of patients are Caucasian).
We acknowledge that our cohort has differences between
the ccRCC tumors in the smokers and non-smokers that
were studied. First, smokers were more likely to be male
than non-smokers. Additionally, smokers in our study
were more likely to have later stage disease compared tonon-smokers in stage 1; however, the stage distributions
were similar between smokers and non-smokers in stages
2-3. Since ANKS1B showed similar results in all 3 stages it
is likely not simply a marker associated with later-stage
disease. With those limitations in mind, the specific
strengths of our design include the use of only clear cell
RCC subtype (the most common histologic subtype),
exclusion of late stage and high grade tumors in the
discovery stages (to focus on events linked to early
ccRCC development), use of packyears > 20 years to define
smokers (those at theorized high exposure to smoking
carcinogens) and access to data on obesity in order to
account for the other primary risk factor for ccRCC.
Our study was designed specifically to identify smoking-
related molecular alterations that are associated with ccRCC
development. As a result, we evaluated patient-matched
tumor and normal kidney samples from both smokers
and non-smokers. Thus, our potential targets of interest
were those that had a statistically significant smoking
status-by-tissue type interaction. It is worth noting that
if cancer is not of interest and future investigators are
interested in simply identifying genes that are associated
with only smoking, our publicly available data could be
further explored to identify genes with a significant smok-
ing main effect.
Conclusion
In summary, we demonstrated that ANKS1B expression
is associated with smoking-related ccRCC. Interestingly,
ANKS1B was recently shown to be associated with can-
cer by Lin et al. [12], where they showed that 2 SNPs in
ANKS1B are associated with risk of lung cancer. Here,
we showed that ANKS1B is under expressed in ccRCC
tumor tissue in comparison to patient-matched normal.
Given the role of ANKS1B as an enhancer of apoptosis,
down regulation of this gene could be involved in increas-
ing the risk of ccRCC development.
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